New stock news | Tiantian Biomedical Pharmaceuticals submitted an application to the Hong Kong Stock Exchange to independently develop innovative drugs for allergic diseases and autoimmune diseases.

According to the Zhitong Financial APP, it was learned that on August 21, the Hong Kong Stock Exchange disclosed that Tianchen Biopharmaceutical (Suzhou) Co., Ltd. (referred to as Tianchen Biopharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Guojin Securities (Hong Kong) as the exclusive sponsor.